Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

Tools
- Tools
+ Tools

Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A. and Earl, Helena M. (2013) A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, Volume 108 (Number 4). pp. 866-872. doi:10.1038/bjc.2012.547

[img]
Preview
Text
WRAP_Dunn_bjc2012547a.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download (721Kb) | Preview
Official URL: http://dx.doi.org/10.1038/bjc.2012.547

Request Changes to record.

Abstract

Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom. We report a central review of post-chemotherapy histopathology reports on the surgical specimens, to assess the presence and degree of response.
Methods: A central independent two-reader review (EP and HME) of histopathology reports from post-treatment surgical specimens was performed. The quality and completeness of pathology reporting across all centres was assessed. The reviews included pathological response to chemotherapy (pathological complete response (pCR); minimal residual disease (MRD); and lesser degrees of response), laterality, the number of axillary metastases and axillary nodes, and the type of surgery. A consensus was reached after discussion.
Results: In all, 825 surgical reports from 816 patients were available for review. Out of 4125 data items there were 347 discrepant results (8.4% of classifications), which involved 281 patients. These involved grading of breast response (169 but only 9 involving pCR vs MRD); laterality (6); presence of axillary metastasis (35); lymph node counts (108); and type of axillary surgery (29). Excluding cases with pCR, only 45% of reports included any comment regarding response in the breast and 30% in the axillary lymph nodes.
Conclusion: We found considerable variability in the completeness of reporting of surgical specimens within this national neoadjuvant breast cancer trial. This highlights the need for consensus guidelines among trial groups on histopathology reporting, and the participation of histopathologists throughout the development and analysis of neoadjuvant trials.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RB Pathology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Cancer -- Treatment, Chemotherapy, Histology, Pathological
Journal or Publication Title: British Journal of Cancer
Publisher: Nature Publishing Group
ISSN: 0007-0920
Official Date: 2013
Dates:
DateEvent
2013Published
Volume: Volume 108
Number: Number 4
Page Range: pp. 866-872
DOI: 10.1038/bjc.2012.547
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Cancer Research UK (CRUK), Eli Lilly and Company, National Institute for Health Research (Great Britain) (NIHR), Cambridge Experimental Cancer Medicine Centre
Grant number: C57/A4180 2004–9 (CRUK)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us